

# SUMO1 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP1221a

## **Product Information**

**Application** WB, IHC-P, FC, IF, E

Primary Accession P63165

Other Accession O5I0H3, A7WLH8, P63166, O5E9D1

Reactivity Human

**Predicted** Bovine, Mouse, Pig, Rat

Host Rabbit
Clonality Polyclonal
Isotype Rabbit IgG
Calculated MW 11557
Antigen Region 1-30

## **Additional Information**

**Gene ID** 7341

Other Names Small ubiquitin-related modifier 1, SUMO-1, GAP-modifying protein 1, GMP1,

SMT3 homolog 3, Sentrin, Ubiquitin-homology domain protein PIC1, Ubiquitin-like protein SMT3C, Smt3C, Ubiquitin-like protein UBL1, SUMO1,

SMT3C, SMT3H3, UBL1

**Target/Specificity**This SUMO1 antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 1-30 amino acids from the N-terminal

region of human SUMO1.

**Dilution** WB~~1:1000 IHC-P~~1:100~500 FC~~1:10~50 IF~~1:10~50 E~~Use at an assay

dependent concentration.

**Format** Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation

followed by dialysis against PBS.

**Storage** Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions** SUMO1 Antibody (N-term) is for research use only and not for use in

diagnostic or therapeutic procedures.

## **Protein Information**

Name SUMO1

### **Synonyms**

SMT3C, SMT3H3, UBL1

## **Function**

Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post- translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1 (PubMed:19223394). Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFHX3 (PubMed:24651376).

#### **Cellular Location**

Nucleus membrane. Nucleus speckle {ECO:0000250 | UniProtKB:P63166}. Cytoplasm. Nucleus, PML body. Cell membrane. Nucleus. Note=Recruited by BCL11A into the nuclear body (By similarity). In the presence of ZFHX3, sequesterd to nuclear body (NB)-like dots in the nucleus some of which overlap or closely associate with PML body (PubMed:24651376) {ECO:0000250 | UniProtKB:P63166, ECO:0000269 | PubMed:24651376}


# **Background**

Covalent modification of target lysines by SUMO (small ubiquitin-like modifier) modulates processes such as protein localization, transcription, nuclear transport, mitosis, DNA replication and repair, signal transduction, and viral reproduction. SUMO does not seem to be involved in protein degradation and may in fact function as an antagonist of ubiquitin in the degradation process. The SUMO family consists of SUMO1 and closely related homologs SUMO2, SUMO3, and SUMO4. Sumoylation has been shown to regulate a wide range of proteins, including MDM2, PIAS, PML, RanGAP1, RanBP2, p53, p73, HIPK2, TEL, c-Jun, Fas, Daxx, TNFRI, Topo-I, Topo-II, PARK2, WRN, Sp100, IkB-alpha, Androgen receptor (AR), GLUT1/4, CaMK, DNMT3B, TDG, HIF1A, CHD3, EXOSC9, RAD51, and viral targets such as CMV-IE1/2, EBV-BZLF1, and HPV/BPV-E1.

## References

Yang, S.H., et al., Mol. Cell 13(4):611-617 (2004). Bailey, D., et al., J. Biol. Chem. 279(1):692-703 (2004). Ling, Y., et al., Nucleic Acids Res. 32(2):598-610 (2004). Pountney, D.L., et al., Exp. Neurol. 184(1):436-446 (2003). Ohshima, T., et al., J. Biol. Chem. 278(51):50833-50842 (2003).


# **Images**




The anti-SUMO1 polyclonal antibody (Cat. #AP1221a) is used in Western blot to detect SUMO1 in HL-60 cell lysate.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.



SUMO1 Antibody (N-term) (Cat. #AP1221a) flow cytometric analysis of Hela cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.



Confocal immunofluorescent analysis of SUMO1 Antibody (N-term)(Cat#AP1221a) with A375 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (green).Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).

# **Citations**

- The human regulatory protein Ki-1/57 is a target of SUMOylation and affects PML nuclear body formation.
- SUMOvlation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7.
- Carcinogen-induced histone alteration in normal human mammary epithelial cells.
- Regulation of the Ets-1 transcription factor by sumovlation and ubiquitinvlation.
- SUMO modification of the Ets-related transcription factor ERM inhibits its transcriptional activity.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.